MX353550B - Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro. - Google Patents
Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro.Info
- Publication number
- MX353550B MX353550B MX2014004457A MX2014004457A MX353550B MX 353550 B MX353550 B MX 353550B MX 2014004457 A MX2014004457 A MX 2014004457A MX 2014004457 A MX2014004457 A MX 2014004457A MX 353550 B MX353550 B MX 353550B
- Authority
- MX
- Mexico
- Prior art keywords
- semaphorin
- brain barrier
- modulation
- barrier permeability
- binding molecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una cantidad eficaz de un anticuerpo aislado o fragmento del mismo que se une a antígeno, que se une específicamente a semaforina-4D (SEMA4D) para usarse como un medicamento para disminuir la permeabilidad de la barrera hematoencefálica (BBB) en un sujeto con permeabilidad BBB aumentada y un trastorno neuroinflamatorio, donde el anticuerpo o fragmento del mismo que se une a antígeno inhibe específicamente la interacción de semaforina 4D (SEMA4D) con el resceptor de SEMA4D, plexina B1.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161545809P | 2011-10-11 | 2011-10-11 | |
US201161555726P | 2011-11-04 | 2011-11-04 | |
US201261593641P | 2012-02-01 | 2012-02-01 | |
PCT/US2012/059757 WO2013055922A1 (en) | 2011-10-11 | 2012-10-11 | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014004457A MX2014004457A (es) | 2014-06-05 |
MX353550B true MX353550B (es) | 2018-01-18 |
Family
ID=48082436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014004457A MX353550B (es) | 2011-10-11 | 2012-10-11 | Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro. |
Country Status (16)
Country | Link |
---|---|
US (2) | US20130095118A1 (es) |
EP (1) | EP2766093B1 (es) |
JP (2) | JP6395606B2 (es) |
KR (1) | KR101999872B1 (es) |
CN (2) | CN104168956A (es) |
AU (1) | AU2012322721B2 (es) |
BR (1) | BR112014008885B1 (es) |
CA (1) | CA2851805C (es) |
DK (1) | DK2766093T3 (es) |
EA (1) | EA029023B1 (es) |
ES (1) | ES2669209T3 (es) |
IL (1) | IL232072B (es) |
MX (1) | MX353550B (es) |
PT (1) | PT2766093T (es) |
SG (1) | SG11201401458UA (es) |
WO (1) | WO2013055922A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102458468B (zh) | 2009-05-08 | 2018-05-18 | 瓦西尼斯公司 | 抗-cd100抗体和其使用方法 |
US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
KR20210104166A (ko) | 2013-06-25 | 2021-08-24 | 백시넥스 인코포레이티드 | 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도 |
NZ630881A (en) * | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) * | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
US10973930B2 (en) | 2016-02-18 | 2021-04-13 | The Penn State Research Foundation | Generating GABAergic neurons in brains |
EP3445397B1 (en) | 2016-04-22 | 2022-11-09 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
CN109563143A (zh) | 2016-08-02 | 2019-04-02 | 瓦西尼斯公司 | 在牛痘病毒/真核细胞中产生多核苷酸文库的改良方法 |
WO2018052948A1 (en) * | 2016-09-13 | 2018-03-22 | Angiocrine Bioscience, Inc. | Blood-brain barrier comprising engineered endothelial cells |
JP2020510845A (ja) * | 2017-02-22 | 2020-04-09 | バクシネックス インコーポレーティッド | 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法 |
US11427634B2 (en) * | 2017-05-05 | 2022-08-30 | Vaccinex, Inc. | Human anti-semaphorin 4D antibody |
US20190092818A1 (en) * | 2017-09-22 | 2019-03-28 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
US20210032300A1 (en) * | 2018-02-02 | 2021-02-04 | The Penn State Research Foundation | Methods and materials for treating brain injuries |
AU2020211961A1 (en) * | 2019-01-22 | 2021-09-09 | Massachusetts Institute Of Technology | In vitro human blood brain barrier |
US20220220210A1 (en) * | 2019-03-29 | 2022-07-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function |
US11597765B2 (en) | 2020-06-25 | 2023-03-07 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
EP3973979A1 (en) * | 2020-09-25 | 2022-03-30 | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth | A tight junction (zonulae occludentes) protein for use in treating or preventing epilepsy |
CN113456813A (zh) * | 2021-07-26 | 2021-10-01 | 苏州大学 | Semaphorin7A单克隆抗体在制备用于治疗血栓及脑血管疾病药物方面的应用 |
WO2023012314A1 (en) * | 2021-08-05 | 2023-02-09 | Lifearc | Anti-plexin-b1 antibodies |
CN114539204B (zh) * | 2022-03-23 | 2023-08-22 | 福建金兰厚普生物科技有限公司 | 己糖激酶抑制剂及其合成方法和应用 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
PT1325932E (pt) | 1997-04-07 | 2005-06-30 | Genentech Inc | Anticorpos anti-vegf |
JP2001516226A (ja) | 1997-04-11 | 2001-09-25 | デンドレオン コーポレイション | 腫瘍関連性の抗原に対する免疫応答を誘導するための組成物および方法 |
EP0892047A3 (de) * | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
DE69839970D1 (de) | 1998-11-10 | 2008-10-16 | Univ Rochester | Methoden zu herstellung von genbanken |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
AU2913801A (en) | 1999-12-23 | 2001-07-03 | Cornell Research Foundation Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
CN1329060A (zh) | 2000-06-19 | 2002-01-02 | 上海博德基因开发有限公司 | 一种新的多肽——人semaphorin蛋白9和编码这种多肽的多核苷酸 |
DE60233509D1 (de) | 2001-06-20 | 2009-10-08 | Fibron Ltd | Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20080219974A1 (en) | 2002-03-01 | 2008-09-11 | Bernett Matthew J | Optimized antibodies that target hm1.24 |
EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
US7351803B2 (en) | 2002-05-30 | 2008-04-01 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
CN1788017B (zh) * | 2003-02-10 | 2013-04-24 | to-BBB控股股份有限公司 | 炎症状态下在血脑屏障中差异表达的核酸 |
KR20180014881A (ko) | 2003-05-30 | 2018-02-09 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
CA2538763C (en) | 2003-09-11 | 2015-05-05 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
AU2004296184B2 (en) | 2003-12-04 | 2010-12-16 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
CA2548282A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
PL1773885T3 (pl) | 2004-08-05 | 2010-09-30 | Genentech Inc | Humanizowani antagoniści anty c-met |
US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
AU2006235271B2 (en) | 2005-04-07 | 2011-05-19 | Novartis Vaccines And Diagnostics Inc. | SEMA4D in cancer diagnosis, detection and treatment |
EP1952147A2 (en) | 2005-11-16 | 2008-08-06 | Novartis AG | Biomarkers for anti-nogo-a antibody treatment in spinal cord injury |
JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
WO2008025020A2 (en) | 2006-08-25 | 2008-02-28 | Seattle Genetics, Inc. | Cd30 binding agents and uses thereof |
US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
EP2436696B8 (en) * | 2007-01-05 | 2017-12-13 | University of Zurich | Anti-beta-amyloid antibody and uses thereof |
WO2008100995A1 (en) * | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
CA2678618C (en) | 2007-02-21 | 2019-03-12 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cd1d molecules |
AU2008341050B2 (en) | 2007-12-26 | 2013-10-24 | Vaccinex, Inc. | Anti-C35 antibody combination therapies and methods |
US20090181035A1 (en) | 2008-01-10 | 2009-07-16 | Genentech, Inc. | Plexind1 agonists and their use |
CN102458468B (zh) | 2009-05-08 | 2018-05-18 | 瓦西尼斯公司 | 抗-cd100抗体和其使用方法 |
DK2429585T3 (en) | 2009-05-15 | 2018-07-30 | Irx Therapeutics Inc | VACCINE IMMUNOTHERAPY |
JP5500944B2 (ja) | 2009-10-29 | 2014-05-21 | 三菱電機株式会社 | 加熱調理器 |
US8834883B2 (en) | 2010-06-14 | 2014-09-16 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
JP6097690B2 (ja) | 2010-09-02 | 2017-03-15 | ヴァクシネックス, インコーポレイテッド | 抗cxcl13抗体およびそれを用いる方法 |
DK2711023T3 (en) | 2011-05-13 | 2017-10-16 | Nat Univ Corp Tokyo Medical & Dental Univ | osteogenesis |
US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
KR102090969B1 (ko) | 2012-03-02 | 2020-03-19 | 백시넥스 인코포레이티드 | B 세포-매개 염증 질환의 치료 방법 |
US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
KR102176962B1 (ko) | 2013-01-31 | 2020-11-10 | 백시넥스 인코포레이티드 | 면역글로불린 a 수준을 증가시키기 위한 방법 |
US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
KR20210104166A (ko) | 2013-06-25 | 2021-08-24 | 백시넥스 인코포레이티드 | 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도 |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
EP3445397B1 (en) | 2016-04-22 | 2022-11-09 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
CN109563143A (zh) | 2016-08-02 | 2019-04-02 | 瓦西尼斯公司 | 在牛痘病毒/真核细胞中产生多核苷酸文库的改良方法 |
JP2020510845A (ja) | 2017-02-22 | 2020-04-09 | バクシネックス インコーポレーティッド | 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法 |
-
2012
- 2012-10-11 AU AU2012322721A patent/AU2012322721B2/en active Active
- 2012-10-11 PT PT128396017T patent/PT2766093T/pt unknown
- 2012-10-11 CA CA2851805A patent/CA2851805C/en active Active
- 2012-10-11 DK DK12839601.7T patent/DK2766093T3/en active
- 2012-10-11 EA EA201490768A patent/EA029023B1/ru not_active IP Right Cessation
- 2012-10-11 EP EP12839601.7A patent/EP2766093B1/en active Active
- 2012-10-11 BR BR112014008885-3A patent/BR112014008885B1/pt active IP Right Grant
- 2012-10-11 US US13/649,651 patent/US20130095118A1/en not_active Abandoned
- 2012-10-11 KR KR1020147012547A patent/KR101999872B1/ko active IP Right Grant
- 2012-10-11 MX MX2014004457A patent/MX353550B/es active IP Right Grant
- 2012-10-11 CN CN201280059376.9A patent/CN104168956A/zh active Pending
- 2012-10-11 CN CN201910351743.6A patent/CN110105452A/zh active Pending
- 2012-10-11 WO PCT/US2012/059757 patent/WO2013055922A1/en active Application Filing
- 2012-10-11 JP JP2014535877A patent/JP6395606B2/ja active Active
- 2012-10-11 ES ES12839601.7T patent/ES2669209T3/es active Active
- 2012-10-11 SG SG11201401458UA patent/SG11201401458UA/en unknown
-
2014
- 2014-04-10 IL IL232072A patent/IL232072B/en active IP Right Grant
-
2017
- 2017-06-30 JP JP2017129377A patent/JP2017193569A/ja active Pending
-
2019
- 2019-06-06 US US16/433,496 patent/US11534488B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PT2766093T (pt) | 2018-05-18 |
JP6395606B2 (ja) | 2018-09-26 |
AU2012322721A1 (en) | 2013-05-16 |
CA2851805A1 (en) | 2013-04-18 |
IL232072B (en) | 2021-01-31 |
KR101999872B1 (ko) | 2019-07-12 |
JP2017193569A (ja) | 2017-10-26 |
CN110105452A (zh) | 2019-08-09 |
US11534488B2 (en) | 2022-12-27 |
US20190358321A1 (en) | 2019-11-28 |
DK2766093T3 (en) | 2018-06-06 |
SG11201401458UA (en) | 2014-07-30 |
US20130095118A1 (en) | 2013-04-18 |
EP2766093A1 (en) | 2014-08-20 |
WO2013055922A1 (en) | 2013-04-18 |
CA2851805C (en) | 2021-12-28 |
ES2669209T3 (es) | 2018-05-24 |
EA029023B1 (ru) | 2018-01-31 |
AU2012322721B2 (en) | 2016-05-05 |
MX2014004457A (es) | 2014-06-05 |
EP2766093B1 (en) | 2018-02-21 |
JP2014530239A (ja) | 2014-11-17 |
EP2766093A4 (en) | 2015-03-25 |
IL232072A0 (en) | 2014-05-28 |
EA201490768A1 (ru) | 2014-09-30 |
BR112014008885B1 (pt) | 2021-02-17 |
KR20140076616A (ko) | 2014-06-20 |
BR112014008885A2 (pt) | 2017-04-18 |
CN104168956A (zh) | 2014-11-26 |
NZ623856A (en) | 2016-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX353550B (es) | Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro. | |
MX347164B (es) | Anticuerpos anti-il-36r. | |
MY188469A (en) | Low affinity blood brain barrier receptor antibodies and uses therefor | |
WO2012031250A8 (en) | Compositions for labeling nerves and methods of use | |
PH12014502406B1 (en) | Anti-il-23p19 antibodies | |
WO2011110642A3 (en) | Monoclonal antibodies against c-met | |
MX2014008102A (es) | Inmunoglobulinas de dominio variable dual contra receptores. | |
MX2021007663A (es) | Molecula de union al antigeno especifico para el tejido objetivo. | |
MX347590B (es) | Anticuerpos del cea. | |
EA201492067A1 (ru) | Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта | |
MX2016004551A (es) | Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis. | |
MX2013005015A (es) | Anticuerpos anti-il-23. | |
UA115402C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським | |
EA201390472A1 (ru) | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты | |
MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
WO2014106001A3 (en) | Dual specific binding proteins having a receptor sequence | |
MX2014002996A (es) | Anticuerpos anti - egfr/anti - igf-1r bisespecificos. | |
MX2015005757A (es) | Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3. | |
MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
WO2012138708A8 (en) | Mhc engagement and clip modulation for the treatment of disease | |
PH12015501980A1 (en) | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same | |
TN2014000207A1 (en) | Anti il-36r antibodies | |
GB201019824D0 (en) | Radioiodination method | |
TN2013000186A1 (en) | Anti-il-23 antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |